Rituximab for the treatment of type II mixed cryoglobulinemia
Open Access
- 9 August 2002
- journal article
- letter
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (8), 2252-2254
- https://doi.org/10.1002/art.10345
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Rituximab in a case of cold agglutinin diseaseBritish Journal of Haematology, 2001
- Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Where do we stand?Arthritis & Rheumatism, 2001
- o-Raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbitsBlood, 2000
- Rituximab for myasthenia gravis developing after bone marrow transplantNeurology, 2000
- Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host DiseaseAnnals of Internal Medicine, 2000
- Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphomaArthritis & Rheumatism, 2000
- IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using RituximabNeurology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998